At a glance
- Relamorelin is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 49 publications mentioning it, including 10 randomized controlled trials and 1 animal-only study.
- ClinicalTrials.gov lists 13 registered studies testing it (0 active).
- FDA's adverse event system (FAERS) holds 1 report mentioning it; 1 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Ghrelin and relamorelin counteract hypoglycemia in mice engrafted with congenital hyperinsulinism stem cell-derived islets.
- HighRes_Builder: improved access and modeling of noncanonical residues for protein structure prediction.
- Peptide Drug Design Using Alchemical Free Energy Calculation: An Application and Validation on Agonists of Ghrelin Receptor.
- Relamorelin in Gastroparesis and Diabetic Gastroparesis: A Meta-Analysis on Its Efficacy and Safety.
- Diabetic Gastroparesis and its Emerging Therapeutic Options: A Narrative Review of the Literature.
- Risk-adjusted management in catheterization procedures for non-ST-segment elevation myocardial infarction: A standard operating procedure pilot study.
- Pharmacotherapeutic advances for chronic idiopathic constipation in adults.
- Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders.
- New Developments in Prokinetic Therapy for Gastric Motility Disorders.
- Diabetic gastroparesis: An overview of pathogenesis, clinical presentation and novel therapies, with a focus on ghrelin receptor agonists.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 13
- Active
- 0
- With posted results
- 6
Conditions studied
Show 3 more studies
| Study | Status | Phase | Start |
|---|---|---|---|
| Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa | Completed | Phase 2 | Nov 2012 |
| Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis | Completed | Phase 2 | Apr 2012 |
| Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis | Completed | Phase 1 | Jul 2011 |
All 13 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 1
- Serious
- 1
- With death outcome
- 0
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.